News

News

Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease

Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye

0 comments

Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019

Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 Ended quarter with $123.5 million in cash  Received IND clearance to

0 comments

Immunovant To Present at the 9th Annual SVB Leerink Global Healthcare Conference

Immunovant To Present at the 9th Annual SVB Leerink Global Healthcare Conference NEW YORK, February 10, 2020 / PRNewswire Immunovant, Inc. (NASDAQ: IMVT) a clinical-stage

0 comments

Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation

Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation Combined company, to be named Immunovant, Inc., will begin trading on Nasdaq under ticker symbol

0 comments

Health Sciences Acquisitions Corporation Sets Date for Special Meeting of Stockholders to Vote on Transaction with Immunovant Sciences Ltd.

Health Sciences Acquisitions Corporation Sets Date for Special Meeting of Stockholders to Vote on Transaction with Immunovant Sciences Ltd. NEW YORK – Health Sciences Acquisitions

0 comments

Immunovant Initiates Dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in Patients with Graves’ Ophthalmopathy (GO)

Immunovant Initiates Dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in Patients with Graves’ Ophthalmopathy (GO) IMVT-1401, a fully human anti-FcRn antibody designed

0 comments

Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT

Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT NEW YORK and

0 comments

Immunovant To Merge with Health Sciences Acquisitions Corporation, Creating New Publicly-Listed FcRn-Focused Company

Immunovant To Merge with Health Sciences Acquisitions Corporation, Creating New Publicly-Listed FcRn-Focused Company Top shareholders of Immunovant post-closing to include Roivant Sciences and blue-chip biotech

0 comments

Immunovant Appoints Robert K. Zeldin as Chief Medical Officer and W. Bradford Middlekauff as General Counsel

Immunovant Appoints Robert K. Zeldin as Chief Medical Officer and W. Bradford Middlekauff as General Counsel NEW YORK and BASEL, Switzerland, August 13, 2019 /PRNewswire/

0 comments

Immunovant Appoints Pete Salzmann as Chief Executive Officer

Immunovant Appoints Pete Salzmann as Chief Executive Officer NEW YORK and BASEL, Switzerland, June 5, 2019 /PRNewswire/ — Immunovant, a biopharmaceutical company focused on developing innovative therapies for patients

0 comments